Abstract
Glucagon-like peptide-1 (GLP-1) is a short peptide that can significantly reduce blood glucose level. Recombination oral long-acting glucagon-like peptide-1 (rolGLP-1), is a GLP-1 analog generated from site-specific mutation of GLP-1. CTB is a non-toxic portion of the cholera toxin and an ideal protein antigen carrier. In this study, we firstly constructed a vector pET-22b (+)-CTB-10×rolGLP-1 to express a fusion protein composed of CTB and ten tandem repeated rolGLP-1 in BL21 (DE3) line of E.coli. The CTB-10×rolGLP-1 was expressed efficiently in the inclusion bodies. The expression product was analyzed by SDS-PAGE electrophoresis and Western blotting. The inclusion bodies were then denatured, refolded and purified by ion exchange chromatography to obtain a high-purity CTB- 10×rolGLP-1. The therapeutic effect of CTB-10×rolGLP-1 was assessed in comparison with 10×rolGLP-1 alone by daily oral-gavage administration up to 10 days in streptozotocin-induced type 2 diabetic mice. The results showed that the level of blood glucose was reduced more effectively and the oral glucose tolerance of mice was improved more significantly with the administration of CTB-10×rolGLP-1. Our results provided a potentially promising oral biological drug for the treatment of type 2 diabetes.
Keywords: Diabetes mellitus, CTB, rolGLP-1, 10×rolGLP-1, fusion polypeptide.
Current Pharmaceutical Biotechnology
Title:Expression of CTB-10×rolGLP-1 in E.coli and Its Therapeutic Effect on Type 2 Diabetes
Volume: 16 Issue: 6
Author(s): Peipei Tu, Zhihua Ma, Haisong Wang, Baicheng Ma, Xiaodan Li, Huikun Duan, Pingzhe Jiang, Miao Li, Ri Wu, Jianhong Zhu and Minggang Li
Affiliation:
Keywords: Diabetes mellitus, CTB, rolGLP-1, 10×rolGLP-1, fusion polypeptide.
Abstract: Glucagon-like peptide-1 (GLP-1) is a short peptide that can significantly reduce blood glucose level. Recombination oral long-acting glucagon-like peptide-1 (rolGLP-1), is a GLP-1 analog generated from site-specific mutation of GLP-1. CTB is a non-toxic portion of the cholera toxin and an ideal protein antigen carrier. In this study, we firstly constructed a vector pET-22b (+)-CTB-10×rolGLP-1 to express a fusion protein composed of CTB and ten tandem repeated rolGLP-1 in BL21 (DE3) line of E.coli. The CTB-10×rolGLP-1 was expressed efficiently in the inclusion bodies. The expression product was analyzed by SDS-PAGE electrophoresis and Western blotting. The inclusion bodies were then denatured, refolded and purified by ion exchange chromatography to obtain a high-purity CTB- 10×rolGLP-1. The therapeutic effect of CTB-10×rolGLP-1 was assessed in comparison with 10×rolGLP-1 alone by daily oral-gavage administration up to 10 days in streptozotocin-induced type 2 diabetic mice. The results showed that the level of blood glucose was reduced more effectively and the oral glucose tolerance of mice was improved more significantly with the administration of CTB-10×rolGLP-1. Our results provided a potentially promising oral biological drug for the treatment of type 2 diabetes.
Export Options
About this article
Cite this article as:
Tu Peipei, Ma Zhihua, Wang Haisong, Ma Baicheng, Li Xiaodan, Duan Huikun, Jiang Pingzhe, Li Miao, Wu Ri, Zhu Jianhong and Li Minggang, Expression of CTB-10×rolGLP-1 in E.coli and Its Therapeutic Effect on Type 2 Diabetes, Current Pharmaceutical Biotechnology 2015; 16 (6) . https://dx.doi.org/10.2174/138920101606150407114815
DOI https://dx.doi.org/10.2174/138920101606150407114815 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
Latest Advancements in Biotherapeutics
The scope of this thematic issue is to comprehensively explore the rapidly evolving landscape of biotherapeutics, emphasizing breakthroughs in precision medicine. Encompassing diverse therapeutic modalities, the issue will delve into the latest developments in monoclonal antibodies, CRISPR/Cas gene editing, CAR-T cell therapies, and innovative drug delivery systems, such as nanoparticle-based ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Gene Therapy for Pituitary Tumors
Current Gene Therapy Ultrasound Contrast Agents: Updated Data on Safety Profile
Current Pharmaceutical Design Diet Control in Pregnant Women with Gestational Diabetes Mellitus
Current Women`s Health Reviews TNF-α and Ghrelin: Opposite Effects on Immune System, Metabolism and Mental Health
Protein & Peptide Letters The Role of Polyunsaturated Fatty Acids (PUFA) in the Treatment of Dyslipidemias
Current Pharmaceutical Design Benzimidazole Derivatives as Kinase Inhibitors
Current Medicinal Chemistry Vitamin D-Binding Protein Acts in the Actin Scavenge System and Can Have Increased Expression During Aspirin Therapy
Current Neurovascular Research Pharmacological Interactions on Blood Pressure Control in Arterial Hypertension, An Issue not to be Overlooked
Cardiovascular & Hematological Disorders-Drug Targets Peroxisome Proliferator-Activated Receptor-γ in Vascular Biology
Cardiovascular & Hematological Disorders-Drug Targets An Update on Autoinflammatory Diseases
Current Medicinal Chemistry Advances and Barriers in Mammalian Cell Encapsulation for Treatment of Diabetes
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Dialogue Between Endothelial Cells and Monocytes/Macrophages in Vascular Syndromes
Current Pharmaceutical Design Metalloproteinases and Metalloproteinase Inhibitors in Age-Related Diseases
Current Pharmaceutical Design Determination of Sitagliptin with Fluorescamine in Tablets and Spiked Serum Samples by Spectrofluorimetry and a Degradation Study
Current Pharmaceutical Analysis Inflammatory Syndrome in Chronic Kidney Disease: Pathogenesis and Influence on Outcomes
Inflammation & Allergy - Drug Targets (Discontinued) Retrospective, Observation Study: Quantitative and Qualitative Effect of Ezetimibe and HMG-CoA Reductase Inhibitors on LDL-Cholesterol: Are There Disappearance Thresholds for Small, Dense LDL and IDL?
Recent Patents on Cardiovascular Drug Discovery Anthocyanins As Modulators of Cell Redox-Dependent Pathways in Non-Communicable Diseases
Current Medicinal Chemistry Editorial: microRNAs: Potential Targets for the Treatment of Cardiovascular Disease
Current Vascular Pharmacology Role of CCK/Gastrin Receptors in Gastrointestinal/Metabolic Diseases and Results of Human Studies Using Gastrin/CCK Receptor Agonists/Antagonists in these Diseases
Current Topics in Medicinal Chemistry The Effect of Drugs and Genetic Factors on the Development and Progression of the Atherosclerotic Process
Current Vascular Pharmacology